In a burst of IPO activity, Ropes & Gray represented, among other clients in other offerings, clients in two life sciences IPOs with an aggregate value of $540 million:

• The underwriters in Bicara Therapeutics’ $315 million initial public offering, which priced on Sept. 12. The deal team included capital markets partner Tom Danielski and counsel Ray Grant. The transaction is the third-largest IPO of the year, according to BioPharma Dive data.
• Zenas BioPharma in its $225 million initial public offering, which priced on Sept. 12 and was announced in a press release. The deal team included capital markets partner Tom Danielski and counsel Nicholas Roper, executive compensation & employee benefits partner Ellen Sueda,health care partner Eve Brunts, and life sciences regulatory & compliance partner Kellie Combs.